pharmaphorum2d
Novo Nordisk tackles supply issues with $11bn Catalent deal
Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...
pharmaphorum2d
Lawmaker asks FTC to probe Novo/Catalent deal
US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give Novo Nordisk control of manufacturing facilities currently operated by ...
Nasdaq4d
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
Novo Nordisk NVO shares have lost 21% in the past ... primarily driven by increased sales of Wegovy and Ozempic. The closing of the Catalent deal in December last year is also expected to help ...
Zacks Investment Research on MSN4d
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...
Thermo Fisher Scientific Inc. (TMO) TD Cowen 45th Annual Health Care Conference - (Transcript)
Well, welcome to the 45th Annual TD Cowen Healthcare Conference. I'm Dan Brennan, follow Tools and Diagnostics. Really pleased to be joined on stage here with Marc Casper, Chairman and President of ...
AbbVie Steps Into The Ring In The Obesity Drug Wars
AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...
Global Microbial Fermentation Technology Market To Increase At A Steady Growth Rate Of ~5% By 2032 | Delveinsight
The microbial fermentation technology market is experiencing significant growth, fueled by the increasing incidence of chronic diseases like cancer a ...
Yahoo Finance4d
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time frame ...
New York Post4d
Novo Nordisk slashing price of Wegovy to $499 a month to uninsured following rival’s move
Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...
The Motley Fool4d
Down 39%. Is Novo Nordisk Stock a Buy on the Dip?
Novo Nordisk stock has fallen roughly 40% from a peak it reached last June. The U.S. Food and Drug Administration recently confirmed Novo Nordisk is producing enough Ozempic and Wegovy to meet demand.
Fierce Pharma2d
With blood and growth disorder bids panning out, Novo Nordisk plots path to rare disease leadership: exec
Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...
The Financial Express2d
Novo Nordisk to launch new therapies in blood and growth disorders after success in diabetes and obesity
Novo Nordisk has become a global sensation with its popular weight loss drugs like Ozempic and Wegovy. On Wednesday, the Danish multinational pharmaceutical company announced that it would begin ...